Niagen Bioscience is trading 8.41% down at $2.31 in pre-market after its November 4 report showed third-quarter revenue of $27.2 million, down 20% year over year and below estimates.
- The company reported a $1.2 million net loss.
- Management expects 2026 ingredient revenue to decline from the prior year amid competitive pressure and tempered its growth outlook.
- Positive cash flow and $69.5 million in cash offer some resilience; earnings and outlook best explain the pre-market drop.